Unexpected peritoneal metastases diagnosed at the time of primary colon cancer resection: controversies regarding options for management
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.For colon cancer patients with unexpected peritoneal metastases found during surgery, a proactive approach combining cytoreductive surgery (CRS) and intraperitoneal chemotherapy offers curative intent, shifting from palliative care.
Area Of Science
- Oncology
- Surgical Oncology
Background
- Synchronous peritoneal metastases in primary colon cancer indicate a high risk of abdominal and pelvic disease progression.
- Preoperative diagnosis often leads to neoadjuvant chemotherapy before cytoreductive surgery (CRS).
- Optimal management for incidentally discovered peritoneal metastases during primary colon cancer resection remains undefined.
Purpose Of The Study
- To present an expert opinion on managing unexpectedly detected peritoneal metastases during primary colon cancer resection.
- To advocate for a shift from palliative to curative-intent treatment strategies for these patients.
Main Methods
- Discussion of treatment options considering patient fitness, colon condition, and institutional capabilities for CRS and intraperitoneal chemotherapy.
- Emphasis on avoiding delays in definitive management to prevent unresectable disease.
Main Results
- The authors argue that prompt, definitive management of unexpected peritoneal metastases can alter the treatment paradigm.
- Delaying treatment can lead to unresectable disease, precluding curative options.
Conclusions
- Unexpectedly detected peritoneal metastases at the time of colon cancer resection warrant a change from palliative to curative-intent management.
- Integrating CRS and intraperitoneal chemotherapy should be considered for these patients to improve outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.